ANL
Adlai Nortye Ltd. Sponsored ADR · NASDAQ
- Sector Commercial Services
- Industry Miscellaneous Commercial Services
- Website adlainortye.com
- Employees(FY) 130
- ISIN US00704R1095
Performance
+2.38%
1W
+5.47%
1M
-74.06%
3M
-60.57%
6M
-61.17%
YTD
-76.73%
1Y
Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.
Technical Analysis of ANL 2024-05-31
Overview:
In analyzing the technical indicators for ANL over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key factors, we aim to offer valuable insights and predictions for the next few days.
Trend Analy...
Recent News & Updates
- 2024-06-03 19:28
- 2024-05-23 21:03
- 2024-05-23 09:03
- 2024-05-22 08:00
- 2024-05-21 20:00
- 2024-05-14 21:40
- 2024-04-24 21:40
- 2024-03-29 08:40
- 2024-03-29 06:00
- 2024-03-28 18:00
- 2023-11-16 18:30
- 2023-10-22 20:12
- 2023-10-03 00:05
- 2023-09-28 14:46
Page 1 of 1
previousnext